References
- Benedetti F , LanotteM, LopianoL, CollocaL. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience147(2) , 260–271 (2007).
- Benedetti F , AmanzioM. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog. Neurobiol.51 , 109–125 (1997).
- Goffaux P , LeonardG, MarchandS, RainvilleP. Placebo analgesia. In: Pharmacology of Pain. Beaulieu P, Lussier D, Porreca F, Dickenson A (Eds). International Association for the Study of Pain Press, Seattle, WA, USA, 451–473 (2010).
- Amanzio M , BenedettiF. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci.19(1) , 484–494 (1999).
- Ossipov MH , DussorGO, PorrecaF. Central modulation of pain. J. Clin. Invest.120(11) , 3779–3787 (2010).
- Marchand S . The physiology of pain mechanisms: from the periphery to the brain. Rheum. Dis. Clin. North Am.34(2) , 285–309 (2008).
- Eide PK . Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain4(1) , 5–15 (2000).
- Woolf CJ , ThompsonSW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain44(3) , 293–299 (1991).
- Yarnitsky D . Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Curr. Opin. Anaesthesiol.23(5) , 611–615 (2010).
- Fields HL , MalickA, BursteinR. Dorsal horn projection targets of ON and OFF cells in the rostral ventromedial medulla. J. Neurophysiol.74(4) , 1742–1759 (1995).
- Porreca F , OssipovMH, GebhartGF. Chronic pain and medullary descending facilitation. Trends Neurosci.25(6) , 319–325 (2002).
- De Felice M , OssipovMH, PorrecaF. Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr. Opin. Neurol.24(3) , 193–196 (2011).
- Nijs J , MeeusM, Van Oosterwijck J et al. Treatment of central sensitization in patients with ‘unexplained‘ chronic pain: what options do we have? Expert Opin. Pharmacother.12(7) , 1087–1098 (2011).
- Enck P , BenedettiF, SchedlowskiM. New insights into the placebo and nocebo responses. Neuron59(2) , 195–206 (2008).
- Landau R , KraftJC, FlintLY et al. An experimental paradigm for the prediction of Post-Operative Pain (PPOP). J. Vis. Exp. 35 , 1671 (2010).
- Leonard G , GoffauxP, MathieuD, BlanchardJ, KennyB, MarchandS. Evidence of descending inhibition deficits in atypical but not classical trigeminal neuralgia. Pain147(1–3) , 217–223 (2009).
- Julien N , GoffauxP, ArsenaultP, MarchandS. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain114(1–2) , 295–302 (2005).
- Reynolds DV . Surgery in the rat during electrical analgesia. Science164(878) , 444–445 (1969).
- Fields HL , BasbaumA, HeinrichRL. Central nervous system mechanisms of pain modulation. In: Wall and Melzack‘s Texbook of pain. McMahon SB, Koltzenburg M. (Eds). Elsevier Limited, Philadelphia, PA, USA, 125–142 (2006).
- Le Bars D , DickensonAH, BessonJM. Diffuse noxious inhibitory controls (DNIC). 1. Effects on dorsal horn convergent neurones in the rat. Pain6(3) , 283–304 (1979).
- Le Bars D , DickensonAH, BessonJM. Diffuse noxious inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones,supraspinal involvement and theoretical implications. Pain6(3) , 305–327 (1979).
- Davies JE , MarsdenCA, RobertsMH. Hyperalgesia and the reduction of monoamines resulting from lesions of the dorsolateral funiculus. Brain Res.261(1) , 59–68 (1983).
- Abbott FV , HongY, FranklinKB. The effect of lesions of the dorsolateral funiculus on formalin pain and morphine analgesia: a dose–response analysis. Pain65(1) , 17–23 (1996).
- Russell IJ . Neurochemical pathogenesis of fibromyalgia. Z. Rheumatol.57(Suppl. 2) , S63–S66 (1998).
- De Souza JB , PotvinS, GoffauxP, CharestJ, MarchandS. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin. J. Pain25(2) , 123–127 (2009).
- Lautenbacher S , RollmanGB. Possible deficiencies of pain modulation in fibromyalgia. Clin. J. Pain13(3) , 189–196 (1997).
- Kosek E , HanssonP. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain70(1) , 41–51 (1997).
- Yarnitsky D , GranotM, Nahman-AverbuchH, KhamaisiM, GranovskyY. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain153(6) , 1193–1198 (2012).
- Goffaux P , RedmondWJ, RainvilleP, MarchandS. Descending analgesia – when the spine echoes what the brain expects. Pain130(1–2) , 137–143 (2007).
- Goffaux P , De Souza JB, Potvin S, Marchand S. Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain145(1–2) , 18–23 (2009).
- Price DD . Psychological and neural mechanisms of the affective dimension of pain. Science288(5472) , 1769–1772 (2000).
- Casey KL , BushnellMC. The imaging of pain: background and rational. In: Pain Imaging. Casey KL, Bushnell MC (Eds). International Association for the Study of Pain Press, Seattle, WA, USA, 1–29 (2000).
- Akil H , MayerDJ. Antagonism of stimulation-producted analgesia by p-CPA, a serotonin synthesis inhibitor. Brain Res.44 , 692–697 (1972).
- Bingel U , TraceyI, WiechK. Neuroimaging as a tool to investigate how cognitive factors influence analgesic drug outcomes. Neurosci. Lett.520(2) , 149–155 (2012).
- Tracey I . Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat. Med.16(11) , 1277–1283 (2010).
- Pollo A , CarlinoE, BenedettiF. Placebo mechanisms across different conditions: from the clinical setting to physical performance. Philos. Trans. R. Soc. Lond. B. Biol. Sci.366(1572) , 1790–1798 (2011).
- Benedetti F , ThoenW, BlanchardC, VighettiS, ArduinoC. Pain as a reward: changing the meaning of pain from negative to positive co-activates opioid and cannabinoid systems. Pain154(3) , 361–367 (2013).
- Levine JD , GordonNC, FieldsHL, BonicaJJ. The role of endorphins in placebo analgesia. In: Advances in Pain Research and Therapy. (Eds). Raven Press, NY, USA, 547 (1979).
- Petrovic P , KalsoE, PeterssonKM, IngvarM. Placebo and opioid analgesia – imaging a shared neuronal network. Science295(5560) , 1737–1740 (2002).
- Bingel U , LorenzJ, SchoellE, WeillerC, BuchelC. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain120(1–2) , 8–15 (2006).
- Eippert F , BingelU, SchoellED et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63(4) , 533–543 (2009).
- Benedetti F , ArmanzioM, CasadioC, OliaroA, MaggiG. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain71 , 135–140 (1997).
- Benedetti F , AmanzioM, ThoenW. Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology213(4) , 791–797 (2011).
- Colloca L , BenedettiF. Nocebo hyperalgesia: how anxiety is turned into pain. Curr. Opin. Anaesthesiol.20(5) , 435–439 (2007).
- Potvin S , GrignonS, MarchandS. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse63(5) , 390–402 (2009).
- Fuente-Fernandez R , RuthTJ, SossiV, SchulzerM, CalneDB, StoesslAJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson‘s disease. Science293(5532) , 1164–1166 (2001).
- Drijgers RL , VerheyFR, TissinghG, van Domburg PH, Aalten P, Leentjens AF. The role of the dopaminergic system in mood, motivation and cognition in Parkinson‘s disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J. Neurol. Sci.320(1–2) , 121–126 (2012).
- de la Fuente-Fernandez R . The powerful pre-treatment effect: placebo responses in restless legs syndrome trials. Eur. J. Neurol.19(10) , 1305–1310 (2012).
- Benedetti F . Placebo-induced improvements: how therapeutic rituals affect the patient‘s brain. J. Acupunct. Meridian Stud.5(3) , 97–103 (2012).
- Flaten MA , AslaksenPM, LybyPS, BjorkedalE. The relation of emotions to placebo responses. Philos. Trans. R. Soc. Lond. B. Biol. Sci.366(1572) , 1818–1827 (2011).
- Lidstone SC , SchulzerM, DinelleK et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. General Psychiatry 67(8) , 857–865 (2010).
- Hall KT , LemboAJ, KirschI et al. Catechol-O-methyltransferase Val158Met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE 7(10) , e48135 (2012).
- Potvin S , LaroucheA, NormandE et al. DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J. Pain10(9) , 969–975 (2009).
- Benedetti F , AmanzioM, RosatoR, BlanchardC. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat. Med.17(10) , 1228–1230 (2011).
- Benedetti F , PolloA, LopianoL, LanotteM, VighettiS, RaineroI. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J. Neurosci.23(10) , 4315–4323 (2003).
- Benedetti F , CarlinoE, PolloA. How placebos change the patient‘s brain. Neuropsychopharmacology36(1) , 339–354 (2011).
- Wager TD . Expectations and anxiety as mediators of placebo effects in pain. Pain115(3) , 225–226 (2005).
- Watson A , El-DeredyW, IannettiGD et al. Placebo conditioning and placebo analgesia modulate a common brain network during pain anticipation and perception. Pain 145(1–2) , 24–30 (2009).
- Leonard G , GoffauxP, MarchandS. Deciphering the role of endogenous opioids in high-frequency TENS using low and high doses of naloxone. Pain151(1) , 215–219 (2010).
- Rief W , BingelU, SchedlowskiM, EnckP. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin. Pharmacol. Ther.90(5) , 722–726 (2011).
- Bingel U , WanigasekeraV, WiechK et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci. Transl. Med. 3(70) , 70ra14 (2011).
- Petersen GL , FinnerupNB, NorskovKN et al. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 153(6) , 1292–1300 (2012).
- Cepeda MS , BerlinJA, GaoCY, WiegandF, WadaDR. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis. Pain Med.13(4) , 575–595 (2012).
- Miller FG , KaptchukTJ. The power of context: reconceptualizing the placebo effect. J. R. Soc. Med.101(5) , 222–225 (2008).
- Lyby PS , AslaksenPM, FlatenMA. Variability in placebo analgesia and the role of fear of pain – an ERP study. Pain152(10) , 2405–2412 (2011).
- Lyby PS , ForsbergJT, AsliO, FlatenMA. Induced fear reduces the effectiveness of a placebo intervention on pain. Pain153(5) , 1114–1121 (2012).
- Vase L , RobinsonME, VerneGN, PriceDD. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain115(3) , 338–347 (2005).
- Vase L , PetersenGL, RileyJL 3rd, Price DD. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain145(1–2) , 36–44 (2009).
- Enck P , BingelU, SchedlowskiM, RiefW. The placebo response in medicine: minimize, maximize or personalize? Nat. Rev. Drug Discov.12(3) , 191–204 (2013).
- Brody H , CollocaL, MillerFG. The placebo phenomenon: implications for the ethics of shared decision-making. J. Gen. Intern. Med.27(6) , 739–742 (2012).
- Vase L , RileyJL 3rd, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain99(3) , 443–452 (2002).
- Voudouris NJ , PeckCL, ColemanG. The role of conditionning and verbal expectancy in the placebo response. Pain43 , 121–128 (1990).